Table 2.
ROC analysis of CSF parameters discriminating different diagnostic groups in the discovery cohort
| Cut‐off point1 | Sensitivity (%) | Specificity (%) | AUC (95% CI) | +LR2 | LR3 | p value (individually) | Coefficient (B) | P value (within model) | |
|---|---|---|---|---|---|---|---|---|---|
| CSF variables | |||||||||
| FTLD (n = 49) vs. CON (n = 23) | |||||||||
| MFG‐E8 | na | na | na | 0.55 (0.405‐0.702) | na | na | 0.428 | −0.0004 | 0.005 |
| tTau | na | na | na | 0.62 (0.487–0.747) | na | na | 0.111 | 0.068 | <0.0001 |
| Aβ42 | 264 | 71 | 69 | 0.75 (0.632–0.859) | 2.29 | 0.42 | 0.001 | −0.010 | <0.0001 |
| FTLD vs. CON model4 | 0.686 | 78 | 83 | 0.90 (0.827–0.976) | 4.59 | 0.27 | <0.0001 | ||
| FTLD (n = 49) vs. non‐FTLD dementia (n = 57) | |||||||||
| YKL40 | na | na | na | 0.60 (0.491–0.708) | na | na | 0.071 | −0.004 | 0.021 |
| pTau | 29.1 | 77 | 67 | 0.80 (0.702–0.877) | 2.3 | 0.3 | <0.0001 | 0.044 | <0.0001 |
| p/tTau | na | na | na | 0.62 (0.512–0.728) | na | na | 0.034 | 2.33 | 0.008 |
| Age | na | na | na | 0.61 (0.503–0.719) | na | na | 0.047 | 0.079 | 0.010 |
| FTLD vs. non‐FTLD dementia model5 | 0.3903 | 90 | 78 | 0.86 (0.781–0.930) | na | na | <0.0001 | ||
| FTLD‐TDP (n = 29) vs. FTLD ‐Tau (n = 20) | |||||||||
| p/t Tau ratio | 0.285 | 80 | 59 | 0.77 (0.641–0.906) | 2 | 0.3 | 0.001 | 7.67 | 0.006 |
| YKL40 | na | na | na | 0.64 (0.476–0.794) | na | na | 0.109 | −0.009 | 0.049 |
| MFG‐E8 | na | na | na | 0.57 (0.411–0.729) | na | na | 0.406 | 0.001 | 0.027 |
| βHexA | na | na | na | 0.57 (0.404–0.737) | na | na | 0.414 | −0.012 | 0.021 |
| βHexA/tHex | na | na | na | 0.54 (0.370–0.708) | na | na | 0.651 | 44.330 | 0.041 |
| Age | na | na | na | 0.52 (0.336–0.696) | na | na | 0.851 | 0.133 | 0.036 |
| TDP vs. Tau model6 | 0.4563 | 80 | 81 | 0.87 (0.772–0.969) | 4.2 | 0.2 | <0.0001 | ||
| FTLD‐TDP (n = 29) vs. CON (n = 30) | |||||||||
| YKL40 | 25.35 | 80 | 62 | 0.78 (0.665–0.901) | 2.1 | 0.3 | <0.0001 | 0.017 | 0.001 |
| MFG‐E8 | na | na | na | 0.44 (0.283–0.589) | na | na | 0.396 | −0.001 | 0.003 |
| Catalase | na | na | na | 0.62 (0.474–0.761) | na | na | 0.122 | 0.430 | 0.024 |
| TDP vs. CON model7 | 0.4431 | 90 | 76 | 0.88 (0.796–0.965) | 3.8 | 0.1 | <0.0001 | ||
AUC, area under the curve; CI, confident interval; LR, likelihood ratio; CON, nondemented controls; FTLD, frontotemporal lobar degeneration.
n.a: not applicable due to the lack of significance.
Selected value of the individual biomarker or combination where the two groups of analysis could be discriminated with the reported sensitivity and specificity.
Positive likelihood: sensitivity/100‐specificity.
Negative likelihood: 100‐sensitivity/specificity.
FTLD vs. CON model: y = 2.94 − 0.0004*MFGE8 + 0.07*tTau − 0.01*Aβ 42.
FTLD vs. non‐FTLD dementia models: y = −6.621 − 0.004*YKL40 + 0.044*pTau + 2.33*p/tTau ratio + 0.79*Age.
TDP vs. Tau model: y = −14.659 − 0.009*YKL40 + 0.001*MFGE8 − 0.012*βHexA activity + 44.33*βHexA/tHex activity ratio + 7.671*p/tTau ratio + 0.133*Age.
TDP vs. CON model: y = −3.193 + 0.017*YKL40 − 0.001*MFGE8 + 0.43*catalase activity.
Markers/models achieving sufficient biomarker performance are highlighted in bold.